Global Human Insulin Market Overview

Insulin is an important hormone in the human body that supports your body convert food into energy and controls blood sugar levels. Diabetes happens when your body either produces inadequate insulin or flops to use it properly. Human insulin is an artificial insulin formed in a laboratory to replicate the insulin found in people. Compared to animal insulin (extracted), human insulin is more pure, reducing antibody creation. Human insulin is a short-acting insulin that treats hyperglycemia induced by Type 1 and Type 2 diabetes. Human insulin is produced using recombinant DNA technology and is identical to endogenously formed insulin.

 

Human Insulin Market experiencing significant growth of XX% every year and is expected to continue its growth during the forecast period. Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, Merck & Co., Inc., and Pfizer Inc. are well-established players in the Global Human Insulin Market. Novo Nordisk A/S is a global leader in the Global Human Insulin Market which offers a broad portfolio of Insulin and Diabetes products. Novo Nordisk A/S’s innovative tablet eliminates the need for injections with GLP-1 – a welcome relief for many people living with type 2 diabetes and partnering with UNICEF to prevent childhood overweight and obesity by creating healthier environments for children. North America region held the dominant segment in the Human Insulin Market in 2023.

 

The Human Insulin Market is mainly driven by the Increase in Incidence of Diabetes Globally and the availability of cost-effective Insulin, which will lead to the rapid growth of the Human Insulin Market in the forecasting year 2024-2030. Side Effects and Safety Concerns are the main challenges in the Human Insulin Market. Based on Type, the Analogue Insulin segment dominated the Human Insulin Market in 2023 with a share of XX%. They offer consistent insulin levels that remain steady for several hours after the injection. Long-acting insulin analogs were designed to better mimic the constant basal insulin component of physiological insulin that moderates fasting plasma glucose. The flexibility and predictability associated with insulin analogs, may minimize patients' distaste for insulin therapy, improve acceptance and adherence, and ultimately contribute to lower medical costs.

 

To get more Insights: Request Free Sample Report

 

Global Human Insulin Market Dynamics

Increase in Incidence of Diabetes Globally to Drive Global Human Insulin Market

Diabetes affects a growing number of people worldwide. Diabetes occurrence varies by area, with the Middle East and North Africa viewing the maximum rates. Type 1 diabetes accounts for only 10% of cases, while Type 2 diabetes accounts for the huge majority of cases or remaining instances. It is typically linked to lifestyle options like obesity and physical inactivity. As these risk features become progressively widespread, the number of diabetics rises. In the UK, 4.6 million individuals live with diabetes. Additionally, the number could be higher, at 1.5 million individuals, with type 2 diabetes that is not diagnosed. Worldwide, 578 million adults aged 21-80 live with diabetes.

 

The projection is set to rise to 657 million in 2030 and 802 million in 2050. More than 4 in 5 adults having diabetes live in low and middle-income countries. Worldwide 6.9 million deaths were reported in 2021.  1 in every 5 seconds. Diabetes has put at stake a minimum of USD 990 billion in health expenditure an increase of 328% in the past 20 years. Egypt, Jordan, Malaysia, Mexico, Pakistan, Papua New Guinea, Saudi Arabia, Sudan, Suriname, Syria, Tanzania, and Turkey have some of the highest rates of diabetes in their populations which drives the Human Insulin Market.

 

Even a 1% increase in a patient’s HbA1c level can indicate an increased risk of complications. Conversely, the National Diabetes Education Program reports that reducing your HbA1c by only 1% may reduce diabetes-related death by 21%, reduce heart attack by 14%, and reduce complications with eyes, kidneys, or nerves by 37%. Diabetes experienced the most rapid growth among causes of health loss after adjusting for age and population size.

 

• In March 2024, the FDA approved the first Over the Counter Continuous Glucose Monitor (CGM), the Dexcom G7. This device allows people with diabetes to track their glucose levels without a prescription.
• The National Framework for Diabetes Act was passed in June 2021, requiring the federal Minister of Health to develop a national framework to improve access to diabetes prevention and treatment, leading to better health outcomes for Canadians.

 

The availability of cost-effective Insulin drives the Global Human Insulin Market.

The rise of generic insulin options and increased competition has led to price reductions, making it more accessible to a wider patient population. This affordability boost has significantly expanded the market for diabetes drugs, encouraging greater adherence to treatment schedules and improving overall diabetes management. For individuals with type 1 diabetes and many with type 2, insulin is a lifesaving drug to manage their disease because a majority of patients use insulin, its affordability is related to access to care and better health outcomes. This holds considerable market share due to the large population under medication.

 

The advancement of cheap insulin options, like biosimilars and generics, has greatly enhanced insulin availability worldwide, leading to the expansion of the global human insulin market. The increased accessibility, alongside cheaper insulin options, allows a broader group of patients to access it. The introduction of biosimilar insulin, nearly identical copies of original insulin products, has increased competition and driven down prices, particularly in some LMICs and European countries, with some estimates suggesting a 50-70% decrease in prices compared to branded insulin.

 

• In 2023, Eli Lilly announced a 70% price reduction on its most commonly prescribed insulin, Humalog, and its non-branded insulin.
• According to the report published in April 2023 by Providence Veterans Affairs Medical Center, prescribers' adoption of SGLT2Is (GLP-1 analogs) is increasing over time, compared with sulfonylureas and other diabetes drugs.

 

Global Human Insulin Market Challenges

Side Effects and Safety Concerns

Insulin is essential for managing diabetes, but insulin therapy comes with specific risks. Some of the most common side effects are Shakiness, Sweating, Dizziness, Confusion, Fast heartbeat, and Hunger Careful monitoring is necessary for hypoglycemia, a frequent side effect characterized by low blood sugar levels. Extended use of insulin increases body weight. While not common, allergic responses may happen. Moreover, insulin resistance can gradually develop in the body, leading to the need for higher medication doses. Following a consistent insulin routine is crucial, however, prolonged use could raise the likelihood of heart issues, stroke, and eye and kidney difficulties, and potentially result in mortality.

 

Nevertheless, the advantages of these drugs usually surpass the disadvantages for most patients. Headaches can occur when initiating or adjusting insulin dosage. Although headaches can be caused by both low and high blood sugar levels, insulin can lead to the retention of sodium and fluid in the body, a condition referred to as edema. Retaining too much fluid can particularly impact your arms and legs. Injecting insulin in the same area frequently can cause fat deposits to form under your skin, making your skin look lumpy. It can also destroy fat, causing indentation of your skin.

 

This issue is called localized lipodystrophy. Frequent rotation of injection sites is important as it can reduce the absorption of injected insulin. Individual’s bodies develop antibodies to synthetic insulin in uncommon instances due to its slight difference from natural insulin. These antibodies could disrupt the effectiveness of the insulin produced and it requires very large doses of insulin which is a main challenge in the Human Insulin Market.

 

• According to "Investigation of Adverse Drug Reactions in Hospitalized Patients with diabetes mellitus in an International Journal" found that hypoglycemia was responsible for 63.72% of adverse drug reactions in hospitalized patients with diabetes mellitus.

 

Global Human Insulin Market Segment Analysis

Based on Type, the Analogue Insulin segment dominated the Human Insulin Market in 2023 with a share of XX%. They offer consistent insulin levels that remain steady for several hours after the injection. Long-acting insulin analogs were designed to better mimic the constant basal insulin component of physiological insulin that moderates fasting plasma glucose.  Insulin analogs are quickly absorbed and begin acting within five to 15 minutes, insulins aspart, glulisine, lispro, and the analogue premixes may be injected immediately before or soon after a meal. Severe hypoglycemia occurred much less frequently in patients with type 2 diabetes and was even less likely to occur with insulin analogs.

 

Analog insulin shows better adherence to therapy and glycemic control. Their effects start within 60-90 minutes, reaching peak effectiveness in about 5 hours, then slowly decreasing over the next 12-24 hours. Insulin analogs are produced the same as human insulin, with genetic modification to alter their effects on the body. Insulin analogs have a unique chemical composition and rapidly decrease blood sugar levels after injection. These analogs have reduced clumping and more consistent absorption. The onset of action of human insulin is generally slower compared to insulin analogs. Insulin analogs begin working within just 5 to 10 minutes after injection. Long-lasting insulin analogs might lead to lower weight increases compared to other insulin varieties.

 

Insulin analogs might lead to fewer occurrences of low blood sugar, particularly during nighttime. Insulin analogs offer a more consistent duration of action patterns. Long-acting insulin analogs remain active for a whole day and need fewer frequent injections compared to human insulin. insulin analogs provide dosing flexibility, which may improve patient satisfaction and adherence to therapy and are associated with a lower risk of hypoglycemia and better postprandial and fasting glycemic control. The flexibility and predictability associated with insulin analogs, may minimize patients' distaste for insulin therapy, improve acceptance and adherence, and ultimately contribute to lower medical costs.

 

• In September 2023, the Chinese company Tonghua Dongbao Pharmaceutical gave Meitheal Pharmaceuticals the exclusive rights to market three insulin biosimilars in the United States. Included in these biosimilars are the extended-release insulin glargine along with two fast-acting insulins, insulin lispro, and insulin aspart

 

Global Human Insulin Market Regional Insights

North America dominated the Global Human Insulin Market and accounted for an XX% share in 2023. due to its large diabetic patient population, the rising number of obesity in people, fluctuating lifestyles, significant occurrence of type 1 and type 2 diabetes, a strong pharmaceutical sector with top insulin producers including Eli Lilly and Company and Becton, Dickinson, sophisticated healthcare facilities able to handle diabetes, and a large population able to afford insulin therapy and growing healthcare expenditures have boosted the growth of the Human Insulin Market.

 

The National Diabetes Statistics Report stated that 38.4 million adults in the U.S., which accounted for 11.6% of the population, were diagnosed with diabetes in 2022. As per the American Diabetes Association, approximately 1.4 million Americans receive a diabetes diagnosis annually. In North America, diabetes accounted for 18.4% of deaths in individuals aged 20-64, who are considered to be in their working years. Diabetes ranks as a top cause of death in Canada and North America, with 11.3 million Canadians (1 in 3) having diabetes or prediabetes in 2020.

 

• By 2045, IDF projections show that 1 in 8 adults, approximately 783 million, will be living with diabetes, an increase of 46%. 
• The National Framework for Diabetes Act was passed in June 2021, requiring the federal Minister of Health to develop a national framework to improve access to diabetes prevention and treatment, leading to better health outcomes for Canadians.

 

Following North America, Europe is the second largest market for Human Insulin because of reasons like an aging population, widespread diabetes, and a high-quality healthcare system. Whereas Asia Pacific holds the third position because of growing elderly populations, more collaborations in developing biosimilars, the global expansion of major corporations, a huge patient base, ongoing economic growth, and increased demand for superior treatment.

 

In 2022, Biocon secured a 3-year, USD 90 million contract from the Ministry of Health Malaysia for supplying Insugen, recombinant human insulin. This deal reinforces Biocon's presence and commitment to emerging markets like Malaysia.

Global Human Insulin Market Scope

Global Human Insulin Market
Market Size in 2023	USD 27.11 billion
Market Size in 2030	USD 40.49 billion
CAGR (2024-2030)	5.9%
Historic Data	2018-2022
Base Year	2023
Forecast Period	2024-2030
Global Human Insulin Market Segments	By Type             Analogue Insulin Long-acting Fast-acting Premix Traditional Human Insulin Long-acting Short-acting Fast-acting Premix
	By Diabetes Type Type 1 Diabetes Type 2 Diabetes
	By Distribution Channel Retail Pharmacies Hospital Pharmacies Online Pharmacies

 

Global Human Insulin Market by Region

• Novo Nordisk A/S
• Sanofi S.A.
• Eli Lilly and Company
• Merck & Co., Inc.
• Biocon Limited
• Pfizer Inc.
• Johnson & Johnson
• Roche Holding AG
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• Wockhardt Ltd.
• Gan & Lee Pharmaceuticals
• Adocia S.A.
• Oramed Pharmaceuticals Inc.